National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
Topics
- Arthritis (1)
- Cancer (1)
- Cancer: Cervical Cancer (1)
- Caregiving (1)
- Children/Adolescents (2)
- Communication (1)
- COVID-19 (2)
- Education: Patient and Caregiver (1)
- Evidence-Based Practice (1)
- Healthcare Costs (3)
- Health Promotion (2)
- (-) Infectious Diseases (9)
- (-) Prevention (9)
- Provider: Clinician (1)
- Provider: Physician (1)
- Public Health (2)
- Risk (1)
- Sexual Health (5)
- Social Media (1)
- (-) Vaccination (9)
- Women (2)
- Young Adults (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 9 of 9 Research Studies DisplayedMiller ME, Rahim MQ, Coven SL
Pediatric hematology and oncology physician and nurse practitioner views of the HPV vaccine and barriers to administration.
This study’s goal was to examine provider views regarding HPV vaccination for pediatric survivors of cancer and pediatric patients with sickle cell disease. The authors conducted qualitative interviews with 20 pediatric hematology/oncology physicians and nurse practitioners. They found that 90% of interviewees support HPV vaccination in their population. The number of providers who reported that they counsel about HPV or provide HPV vaccination was 45%, even in stem cell and sickle cell clinics, where other childhood vaccines are commonly provided. Clinicians identified provider-level, clinic-level, and system-level barriers to giving the HPV vaccination, that included but was not limited to time/flow constraints, lack of resources, and continued education regarding the HPV vaccine.
AHRQ-funded; HS026390.
Citation: Miller ME, Rahim MQ, Coven SL .
Pediatric hematology and oncology physician and nurse practitioner views of the HPV vaccine and barriers to administration.
Hum Vaccin Immunother 2023 Aug 1; 19(2):2224089. doi: 10.1080/21645515.2023.2224089..
Keywords: Vaccination, Sexual Health, Infectious Diseases, Prevention, Provider: Clinician, Provider: Physician
Glenn BA, Nonzee NJ, Tieu L
Human papillomavirus (HPV) vaccination in the transition between adolescence and adulthood.
This study looked at the barriers to human papillomavirus (HPV) vaccination among young adults receiving care at the student health center of a large public university. The authors conducted semi-structured interviews (n=27) and four focus groups with undergraduate and graduate students (n=18) and semi-structured interviews with 6 health care providers. The interviews and focus groups explored perceived risk of HPV infection, benefits of the HPV vaccine, and motivations for and barriers to HPV vaccination. Many students cited their parents’ views and recommendations from their medical providers as influential on their decision-making process. Cervical cancer prevention was considered the main benefit of the HPV vaccine and sexual activity was a risk factor for HPV infection. Students often lacked knowledge about the vaccine’s benefit for males. Safety and side effects of the vaccine perceived as new were also cited. Providers’ vaccine recommendations were impacted by health system factors including clinical infrastructure, office visit priorities, and processes for recommending and documentation vaccination. Providers suggested various promotion strategies including improving the timing and messaging of outreach efforts on campus and bolstering clinical infrastructure.
AHRQ-funded; HS000046.
Citation: Glenn BA, Nonzee NJ, Tieu L .
Human papillomavirus (HPV) vaccination in the transition between adolescence and adulthood.
Vaccine 2021 Jun 8;39(25):3435-44. doi: 10.1016/j.vaccine.2021.04.019..
Keywords: Young Adults, Sexual Health, Infectious Diseases, Vaccination, Prevention, Cancer: Cervical Cancer, Cancer, Women
Bartsch SM, O'Shea KJ, Wedlock PT
The benefits of vaccinating with the first available COVID-19 coronavirus vaccine.
This study’s objective was to determine quantitatively the benefits of early vaccination for COVID-19 even if later on in the pandemic a latter vaccine has substantially higher efficacy. The team developed this model in 2020 before vaccinations became available. For example if a vaccine with 50% efficacy becomes available when 10% of the population has already been infected, waiting until 40% of the population are infected for a vaccine with 80% efficacy results in 15.6 million additional cases and 1.5 million additional hospitalizations, costing $20.6 billion more in direct medical costs and $12.4 billion more in productivity losses.
AHRQ-funded; HS028165.
Citation: Bartsch SM, O'Shea KJ, Wedlock PT .
The benefits of vaccinating with the first available COVID-19 coronavirus vaccine.
Am J Prev Med 2021 May;60(5):605-13. doi: 10.1016/j.amepre.2021.01.001..
Keywords: COVID-19, Vaccination, Healthcare Costs, Prevention, Infectious Diseases
Bartsch SM, O'Shea KJ, Ferguson MC
Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention.
This study examined the needed efficacy and coverage of a COVID-19 vaccine to prevent or stop the pandemic. Simulation experiments were conducted at 60-80% efficacy rates. At 60% efficacy, vaccination coverage needs to be 100%. If the coverage rate is reduced to 75%, the efficacy needs to be 70% and up to 80% when coverage drops to 60%. These findings show that the vaccine needs to have at least an efficacy rate of 70% to prevent an epidemic and at least 80% to extinguish an epidemic without any other measures such as social distancing.
AHRQ-funded; HS023317.
Citation: Bartsch SM, O'Shea KJ, Ferguson MC .
Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention.
Am J Prev Med 2020 Oct;59(4):493-503. doi: 10.1016/j.amepre.2020.06.011..
Keywords: Vaccination, COVID-19, Public Health, Prevention, Evidence-Based Practice, Infectious Diseases
Bartsch SM, Asti L, Stokes-Cawley OJ
The potential economic value of a Zika vaccine for a woman of childbearing age.
The authors mapped the Zika vaccine and vaccination characteristic thresholds at which vaccination becomes cost effective, highly cost effective, and cost saving. They developed a Markov model to simulate a woman of childbearing age to follow the potential risk and clinical course of a Zika infection. They found that, in some cases, the vaccine was cost effective when the risk was as low as 0.015%, the cost was as high as $7,500, the efficacy was as low as 25%, and the duration of protection was 1 year. They concluded that the thresholds at which vaccination becomes cost effective and cost saving can provide targets for Zika vaccine development and implementation.
AHRQ-funded; HS023317.
Citation: Bartsch SM, Asti L, Stokes-Cawley OJ .
The potential economic value of a Zika vaccine for a woman of childbearing age.
Am J Prev Med 2020 Mar;58(3):370-77. doi: 10.1016/j.amepre.2019.10.023..
Keywords: Vaccination, Women, Infectious Diseases, Public Health, Healthcare Costs, Prevention
Margolis MA, Brewer NT, Shah PD
Stories about HPV vaccine in social media, traditional media, and conversations.
To understand how stories from media and social interactions shape parents' HPV vaccination decisions, the authors sought to characterize parents' exposure to these stories, as well as associations between story exposure and vaccination behavior. They found that stories of HPV vaccine harms may be associated more strongly with vaccination behavior than stories of HPV vaccine preventable diseases. They recommended that communication campaigns consider strategies to elevate stories of preventable diseases in social and traditional media.
AHRQ-funded; HS000032.
Citation: Margolis MA, Brewer NT, Shah PD .
Stories about HPV vaccine in social media, traditional media, and conversations.
Prev Med 2019 Jan;118:251-56. doi: 10.1016/j.ypmed.2018.11.005..
Keywords: Caregiving, Children/Adolescents, Communication, Education: Patient and Caregiver, Health Promotion, Infectious Diseases, Prevention, Sexual Health, Social Media, Vaccination
Baldwin AS, Denman DC, Sala M
Translating self-persuasion into an adolescent HPV vaccine promotion intervention for parents attending safety-net clinics.
Researchers developed a tablet-based application (in English and Spanish) to elicit parental self-persuasion for adolescent HPV vaccination and evaluated its feasibility in a safety-net population. They found that the self-persuasion application was feasible and resulted in a change in parents' decision stage. Future studies can now test the efficacy of the tablet-based application on HPV vaccination.
AHRQ-funded; HS022418.
Citation: Baldwin AS, Denman DC, Sala M .
Translating self-persuasion into an adolescent HPV vaccine promotion intervention for parents attending safety-net clinics.
Patient Educ Couns 2017 Apr;100(4):736-41. doi: 10.1016/j.pec.2016.11.014.
.
.
Keywords: Children/Adolescents, Health Promotion, Vaccination, Infectious Diseases, Sexual Health, Prevention
Fitzpatrick MC, Shah HA, Pandey A
One Health approach to cost-effective rabies control in India.
The authors developed a data-driven rabies transmission model fit to human rabies autopsy data and human rabies surveillance data from Tamil Nadu, India. They found that highly feasible strategies focused on stray dogs, vaccinating as few as 7% of dogs annually, could very cost-effectively reduce human rabies deaths by 70% within 5 years, and a modest expansion to vaccinating 13% of stray dogs could cost-effectively reduce human rabies by almost 90%. Futher, if owners are willing to bring dogs to central point campaigns at double the rate that campaign teams can capture strays, expanded annual targets become cost-effective.
AHRQ-funded; HS000055.
Citation: Fitzpatrick MC, Shah HA, Pandey A .
One Health approach to cost-effective rabies control in India.
Proc Natl Acad Sci U S A 2016 Dec 20;113(51):14574-81. doi: 10.1073/pnas.1604975113.
.
.
Keywords: Healthcare Costs, Infectious Diseases, Prevention, Vaccination
Yun H, Yang S, Chen L
Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination.
This study was undertaken to evaluate the age-stratified incidence of herpes zoster (HZ) in patients with autoimmune or inflammatory (AI) diseases as compared to older adults for whom the HZ vaccine is currently recommended by the US Centers for Disease Control and Prevention. The researchers found that systemic lupus erythematosus, inflammatory bowel disease, and rheumatoid arthritis are AI diseases associated with a higher risk of HZ compared to that in older adults for whom vaccination is currently recommended, suggesting that individuals with these conditions who are as young as age 40 years could potentially benefit from the HZ vaccine.
AHRQ-funded; HS021694; HS018517.
Citation: Yun H, Yang S, Chen L .
Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination.
Arthritis Rheumatol 2016 Sep;68(9):2328-37. doi: 10.1002/art.39670.
.
.
Keywords: Infectious Diseases, Prevention, Arthritis, Risk, Sexual Health, Vaccination